Published in BMC cancer
Anti-proliferative TKIs appear to enrich for sarcoma CSCs while anti-angiogenic TKIs do not. The rational selection of targeted therapies for sarcoma patients may benefit from an awareness of the differential impact of TKIs on CSC populations.
Published in BMC cancer
We present a new model developed from a community-based SLN database that uses only three rather than eight variables to achieve higher accuracy than the Nomogram for predicting NSLN status in two different datasets.
Published in BMC cancer
We successfully optimized a MSP method for the precise and efficient screening of TGFBI promoter methylation status. Dense methylation of the TGFBI promoter correlated with the extent of TGFBI gene silencing in tumor cell lines and was related to invasiveness of prostate tumors and metastatic status of lung cancer tumors. Thus, TGFBI promoter methy...
Published in BMC cancer
The results suggest that the RAD51C mutations do not predispose to prostate or colorectal cancer.
Published in BMC cancer
Kaposi sarcoma (KS) is a multifocal, vascular lesion of low-grade malignant potential that presents most frequently in mucocutaneous sites. KS also commonly involves lymph nodes and visceral organs. This article deals with the manifestation of KS in unusual anatomic regions. Unusual locations of KS involvement include the musculoskeletal system, ce...
Published in BMC cancer
NEXT NCT01574235, VENICE NCT01627990.
Published in BMC cancer
The study is registered at ClinicalTrials.gov: NCT01830075.
Published in BMC cancer
ClinicalTrials.gov: NCT01316120.
Published in BMC cancer
ClinicalTrials.gov: NCT01372514.
Published in BMC cancer
Clinical Trial Identifier, NCT01553032 (clinicaltrials.gov)EudraCT number: 2010-019748-38.
